Related Experiment Video
Updated: May 12, 2025
03:47
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
676
Artificial Intelligence in the Management of Heart Failure
Baljash Cheema1, Jonathan Hourmozdi2, Adrienne Kline1
1Bluhm Cardiovascular Institute, Center for Artificial Intelligence, Northwestern Medicine, Chicago, IL; Northwestern University, Feinberg School of Medicine, Chicago, IL.
Journal of Cardiac Failure
|May 9, 2025
Summary
Artificial intelligence (AI) offers transformative potential in heart failure management, from diagnosis to personalized treatment. Overcoming implementation barriers like data privacy and trust is crucial for widespread clinical adoption of these advanced AI tools.
Area of Science:
- Cardiology
- Medical Informatics
- Artificial Intelligence
Background:
- Heart failure management presents complex challenges in diagnosis and treatment.
- Artificial intelligence (AI) has emerged as a powerful tool with the potential to significantly improve patient care.
- Numerous AI solutions have been developed over the last decade to address various aspects of heart failure.
Purpose of the Study:
- To review the progress and applications of AI in the diagnosis and management of heart failure.
- To highlight the potential of AI in personalizing patient care through multimodal data integration.
- To identify and discuss the key barriers hindering the clinical implementation of AI in heart failure.
Main Methods:
- Integration of multimodal data, including omics, imaging, signals, and electronic health records.
- Application of state-of-the-art algorithms for tailored patient care.
- Review of existing AI solutions and their impact on heart failure management.
Main Results:
- AI tools can aid in diagnosing risk factors, identifying structural heart disease, improving cardiomyopathy diagnosis, and managing symptomatic heart failure.
- AI enables a more personalized approach to patient care by integrating diverse data sources.
- Significant progress has been made in developing AI solutions for heart failure.
Conclusions:
- AI holds substantial promise for revolutionizing heart failure care.
- Key implementation challenges, including data privacy, model performance, integration, trust, governance, fairness, and bias, must be addressed.
- Further research and development of best practices are essential to accelerate the clinical adoption of AI in heart failure management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
01:22Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
01:22Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291